Biomarker classification, validation, and what to look for in 2017 and beyond

Davis, John W.

doi:10.1111/bju.13790

Cited by 7 publications

(4 citation statements)

References 6 publications

(17 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A cancer biomarker is a biological molecule that suggests the presence of cancer, characterizes cancer, and can derive from cancer itself, or it indicates the response of the body to the existence of cancer [ 57 ]. A diagnostic biomarker is used to determine or confirm a type of cancer [ 57 , 58 ]. A prognostic biomarker is used to identify the likelihood of the outcome of the patients with cancer with or without treatment and on the disease recurrence or progression [ 57 , 58 ].…”

Section: Leukemogenesis and Associated Cell Processesmentioning

confidence: 99%

“…A diagnostic biomarker is used to determine or confirm a type of cancer [ 57 , 58 ]. A prognostic biomarker is used to identify the likelihood of the outcome of the patients with cancer with or without treatment and on the disease recurrence or progression [ 57 , 58 ]. Circulating molecules with diagnostic and prognostic value may be located in PB and its components: plasma or serum, EV, and/or blood peripheral cells.…”

Section: Leukemogenesis and Associated Cell Processesmentioning

confidence: 99%

“…A cancer biomarker is a biological molecule that suggests the presence of ca characterizes cancer, and can derive from cancer itself, or it indicates the response o body to the existence of cancer [57]. A diagnostic biomarker is used to determine or firm a type of cancer [57,58]. A prognostic biomarker is used to identify the likeliho depends on where the molecular machinery is affected.…”

Section: General Description Of Main Type Of Molecules With Potential...mentioning

confidence: 99%

See 2 more Smart Citations

Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia

Álvarez-Zúñiga,

Garza-Veloz,

Martínez-Rendón

et al. 2023

Cancers

View full text Add to dashboard Cite

Acute lymphoblastic leukemia (ALL) is a hematological disease characterized by the dysfunction of the hematopoietic system that leads to arrest at a specific stage of stem cells development, suppressing the average production of cellular hematologic components. BCP-ALL is a neoplasm of the B-cell lineage progenitor. BCP-ALL is caused and perpetuated by several mechanisms that provide the disease with its tumor potential and genetic and cytological characteristics. These pathological features are used for diagnosis and the prognostication of BCP-ALL. However, most of these paraclinical tools can only be obtained by bone marrow aspiration, which, as it is an invasive study, can delay the diagnosis and follow-up of the disease, in addition to the anesthetic risk it entails for pediatric patients. For this reason, it is crucial to find noninvasive and accessible ways to supply information concerning diagnosis, prognosis, and the monitoring of the disease, such as circulating biomarkers. In oncology, a biomarker is any measurable indicator that demonstrates the presence of malignancy, tumoral behavior, prognosis, or responses to treatments. This review summarizes circulating molecules associated with BCP-ALL with potential diagnostic value, classificatory capacity during monitoring specific clinic features of the disease, and/or capacity to identify each BCP-ALL stage regarding its evolution and outcome of the patients with BCP-ALL. In the same way, we provide and classify biomarkers that may be used in further studies focused on clinical approaches or therapeutic target identification for BCP-ALL.

show abstract

Section: Leukemogenesis and Associated Cell Processesmentioning

confidence: 99%

Section: Leukemogenesis and Associated Cell Processesmentioning

confidence: 99%

Section: General Description Of Main Type Of Molecules With Potential...mentioning

confidence: 99%

See 1 more Smart Citation

Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia

Álvarez-Zúñiga,

Garza-Veloz,

Martínez-Rendón

et al. 2023

Cancers

View full text Add to dashboard Cite

show abstract

“…In general, cancer biomarkers can be classified into four groups of ( i ) risk screening, (ii) predictive, (iii) prognostic, and (iv) diagnostic markers [25]. Among them, diagnostic biomarkers, including particular proteins and genes, are vital for assisting the early diagnosis of cancers when the patients have not yet developed any distinctive symptoms.…”

Section: Electrochemical Biosensorsmentioning

confidence: 99%

2D Materials in Development of Electrochemical Point-of-Care Cancer Screening Devices

et al. 2019

View full text Add to dashboard Cite

Effective cancer treatment requires early detection and monitoring the development progress in a simple and affordable manner. Point-of care (POC) screening can provide a portable and inexpensive tool for the end-users to conveniently operate test and screen their health conditions without the necessity of special skills. Electrochemical methods hold great potential for clinical analysis of variety of chemicals and substances as well as cancer biomarkers due to their low cost, high sensitivity, multiplex detection ability, and miniaturization aptitude. Advances in two-dimensional (2D) material-based electrochemical biosensors/sensors are accelerating the performance of conventional devices toward more practical approaches. Here, recent trends in the development of 2D material-based electrochemical biosensors/sensors, as the next generation of POC cancer screening tools, are summarized. Three cancer biomarker categories, including proteins, nucleic acids, and some small molecules, will be considered. Various 2D materials will be introduced and their biomedical applications and electrochemical properties will be given. The role of 2D materials in improving the performance of electrochemical sensing mechanisms as well as the pros and cons of current sensors as the prospective devices for POC screening will be emphasized. Finally, the future scopes of implementing 2D materials in electrochemical POC cancer diagnostics for the clinical translation will be discussed.

show abstract

A Synopsis of Emerging Blood Biomarkers in Trauma, Injury Critical Care, and Recovery: General Overview

Milić

Stankić

2022

Biomarkers in Trauma, Injury and Critical Care

View full text Add to dashboard Cite

Biomarker classification, validation, and what to look for in 2017 and beyond

Cited by 7 publications

References 6 publications

Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia

Circulating Biomarkers Associated with the Diagnosis and Prognosis of B-Cell Progenitor Acute Lymphoblastic Leukemia

2D Materials in Development of Electrochemical Point-of-Care Cancer Screening Devices

A Synopsis of Emerging Blood Biomarkers in Trauma, Injury Critical Care, and Recovery: General Overview

Contact Info

Product

Resources

About